BPC-157 Dissolvable Strips
About BPC-157 Dissolvable Strips
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide comprising a partial sequence of a protein originally isolated from human gastric juice. With the amino-acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22 and a monoisotopic-scale molecular weight of approximately 1419.5 g/mol, it is catalogued under CAS 137525-51-0 and PubChem CID 9941957. The compound is notably stable in aqueous and acidic environments relative to many peptides, a property that has made it a frequent subject in gastrointestinal and connective-tissue research.
In the peer-reviewed literature, BPC-157 has been studied extensively in rodent injury models addressing tendon, ligament, muscle, bone and mucosal repair. Proposed mechanisms center on modulation of angiogenesis (via VEGFR2 and the nitric-oxide / eNOS-Akt axis), fibroblast activity and collagen organization. Helio supplies BPC-157 as a lyophilized powder in 5 mg and 10 mg vials for laboratory research applications. This material is offered for Research Use Only and is not for human or veterinary use.
Format: supplied as dissolvable oral strips (30 per box) — a fast, needle-free research format. Exact per-strip potency is printed on the packaging.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
BPC-157 is a synthetic 15-amino-acid peptide fragment widely studied in tissue-repair, gastrointestinal, and recovery research models.
Supplied as dissolvable oral strips — 30 strips per box — for fast, consistent, needle-free handling in the research setting. Exact per-strip potency is printed on the packaging.
Every batch is independently tested by an ISO 17025-accredited laboratory to ≥99% purity, with a certificate of analysis on file for its exact lot.
For research use only. Not for human or veterinary consumption, diagnosis, or treatment.
Specifications
- MaterialBPC-157 Dissolvable Strips
- Also searched asBPC157, BPC 157, Body Protection Compound 157
- Research AreaRecovery Research
- PresentationDissolvable Strips
- CAS Number137525-51-0
- Molecular FormulaC62H98N16O22
- Molecular Weight1419.5 g/mol
- TypeSynthetic pentadecapeptide
- Receptor / TargetNo single defined receptor; investigated via VEGFR2, nitric oxide (NO) / eNOS-Akt signaling and growth-factor pathways in preclinical models
- PubChem CID9941957 →
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)
- Purity (HPLC)≥99%
- Identity (MS)Confirmed to specification
- TestingAccredited (ISO 17025) third-party laboratory
- DocumentationPer-batch COA →
Preclinical work led largely by Sikiric, Seiwerth, Brcic and colleagues reports that BPC-157 accelerates healing across multiple rodent tissue-injury paradigms, with vascular and nitric-oxide pathways recurring as central mechanistic themes. Documented endpoints include enhanced angiogenesis and VEGF expression, improved tendon and ligament biomechanics, and mucosal protection in gastrointestinal models.
These observations derive from animal and in-vitro experiments; controlled human efficacy has not been established, and no receptor has been definitively identified. All data should be interpreted within an experimental, hypothesis-generating context.
BPC-157 was derived in the 1990s from Body Protection Compound (BPC), a peptide fraction identified in human gastric juice, and has since been characterized across an extensive series of experimental studies (also referenced as PL 14736 in earlier inflammatory-bowel research). It remains an unapproved investigational compound used strictly for laboratory research.
- Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Current Pharmaceutical Design. 2014;20(7):1121-1125.
- Brcic L, Brcic I, Staresinic M, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196.
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. This material is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
Are these research materials third-party tested?
Yes — every batch is analysed by an accredited (ISO 17025) independent laboratory using HPLC and mass spectrometry, with a per-batch Certificate of Analysis.
What purity are the materials?
Materials are verified to 99%+ HPLC purity. Any batch that does not meet the threshold is not released.
Do you provide a Certificate of Analysis (COA)?
Yes. Per-batch COA documentation is provided and is traceable by lot number.
Where do you ship from?
Materials are shipped from the USA in discreet, protective packaging.
Are these products for human use?
No. All materials are sold strictly for laboratory research use only — not for human or animal consumption, diagnosis, treatment, or prevention of any disease.
More Recovery Research materials
RESEARCH USE ONLY · NOT FOR HUMAN OR VETERINARY USE · 21+
